Mersana Therapeutics employs its biodegradable polymer platform (Fleximer®) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas.
Mersana is supported by top-tier investors to advance its oncology pipeline through the clinic. The Company's lead program, XMT-1001, is a Fleximer-camptothecin conjugate that is completing a Phase 1 trial in cancer patients with refractory solid tumors. XMT-1107, a Fleximer-fumagillin conjugate, is expected to enter Phase 1 studies in 2010. Mersana has built an efficient and versatile team to create additional cancer pipeline candidates and to exploit its Fleximer platform in biological applications both independently as well as with strategic partners.
